Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

Clinical and Translational Oncology

Volumn 14, Issue 3, 2012, Pages 207-213

  Chen, Xiaoxia ^a   Sun, Hui ^a   Ren, Shengxiang ^a   Kim Curran, Vikramsingh ^a   Zhang, Ling ^a   Zhou, Songwen ^a   Zhang, Jie ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Chemotherapy; Non small cell lung cancer; Polymorphisms; X ray repair cross complementing group 3; Xeroderma pigmentosum group D

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CODON; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GERIATRIC PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; X RAY REPAIR CROSS COMPLEMENTING GROUP 3 GENE; XERODERMA PIGMENTOSUM GROUP D GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84860757739     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0785-3     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Tahara E, Yasui W, Ito H et al (2009) Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities' Consortium International Symposium. Jpn J Clin Oncol 40:702-708
3. Grønberg BH, Bremnes RM, Fløtten O et al (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as ? rst-line chemotherapy in advanced non-smallcell lung cancer. J Clin Oncol 27:3217-3224
4. Gossage L ,Madhusudan S (2007) Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 11:361-380 (Pubitemid 350274404)
5. Matullo G, Palli D, Peluso M et al (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22:1437-1445 (Pubitemid 32898701)
6. Qiao Y, Spitz MR, Shen H et al (2002) Modulation of repair of ultraviolet damage in the host cell reactivation assay by polymorphic XPC and XPD/ ERCC2 genotypes. Carcinogenesis 23:295-299 (Pubitemid 34224005)
7. Zhou C, Ren S, Zhou S et al (2010) Predictive effects of ERCC1 and XRCC3 SNP on ef? cacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 40:954-960
8. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299-1320
9. Matullo G, Guarrera S, Carturan S et al (2001) DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 92:562-567 (Pubitemid 32319431)
10. de las Peñas R, Sanchez-Ronco M, Alberola V et al (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine- treated non-small-cell lung cancer patients. Ann Oncol 17:668-675
11. Bosken CH, Wei Q, Amos CI et al (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94:1091-1099 (Pubitemid 34830729)
12. Zhang Zl, Zhou CC, Zhang J et al (2007) Relationship between polymorphisms of DNA repair gene XRCC3 and susceptibility to lung cancer. Chin J Tuberculosis Resp Dis 30:1215-1220
13. Schöllnberger H, Manuguerra M, Bijwaard H et al (2006) Analysis of epidemiological cohort data on smoking effects and lung cancer with a multistage cancer model. Carcinogenesis 27:1432-1444 (Pubitemid 43985418)
14. Zienolddiny S, Campa D, Lind H et al (2006) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27:560-567 (Pubitemid 43372885)
15. Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194-203 (Pubitemid 39199306)
16. Ryu JS, Hong YC, Han HS et al (2004): Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44:311-316
17. Rosell-Costa R, Alberola V, Camps C et al (2006) Clinical outcome of gemcitabine (gem)/cisplatin (cis)-vs docetaxel (doc)/cis-treated stage IV non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age. J Clin Oncol 24:7055
18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
19. Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601 (Pubitemid 41103746)
20. Zhou W, Gurubhagavatula S, Liu G et al (2004) Excision repair ross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939-4943 (Pubitemid 39099767)
21. Chen S, Tang D, Xue K et al (2002) DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 23:1321-1325
22. Aloyz R, Xu ZY, Bello V et al (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62:5457-5462
23. Liu L, Yuan P, Wu C et al (2010) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73:110-115
24. Yao CY, Huang XE, Li C et al (2009) Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 10:859-864
25. Tibaldi C, Giovannetti E, Vasile E et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797-1803 (Pubitemid 351469466)
26. Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354 (Pubitemid 39037082)
27. Park DJ, Stoehlmacher J, Zhang W et al (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654-8658 (Pubitemid 34013872)
28. Robert J, Morvan VL, Smith D et al (2005) Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54:171-196 (Pubitemid 40693684)
29. Stohlmacher J (2005) Pharmacogenetics in gastrointestinal tumors. Onkologie 28:435-440 (Pubitemid 41558261)
30. Kweekel DM, Gelderblom H, Guchelaar HJ (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90-105 (Pubitemid 40542888)